Discussion We suggest that for patients with NCFB, an important risk factor predicting benefit
from inhaled antibiotics is a history of frequent pulmonary exacerbations, and a key clinical …

Introduction: Non-cystic fibrosis bronchiectasis (NCFB) results from a permanent and
progressive destruction of the airways leading to poor lung function. NCFB is characterized …

Bronchiectasis is a complex, chronic respiratory condition, characterized by frequent cough
and exertional dyspnea due to a range of conditions that include inherited mucociliary …

Bronchiectasis is a condition defined by irreversible dilation of the bronchi accompanied by
chronic sputum production, decreased lung function, and recurrent exacerbations, that leads …

Abstract Background and Aims The evidence supported the use of nebulized antibiotics in
non‐cystic fibrosis (non‐CF) bronchiectasis is indefinite. A meta‐analysis was performed to …

Bronchiectasis is a condition characterized by irreversible dilatation of the airways 1
resulting from changes in the elastic and muscular components of the bronchial wall. The …

Background Inhaled antibiotics (IA) in non-cystic fibrosis bronchiectasis (NCFB) are
recommended by some clinical practice guidelines for prevention or treatment of NCFB …

Antibiotics have a role in the management of acute exacerbations of bronchiectasis and may
also benefit selected subsets of patients with bronchiectasis as a part of a long-term …

There are strong data supporting using the use of aerosolized antibiotics for the treatment of
Gram-negative infections in patients with cystic fibrosis (CF). The regular use of aerosol …

Abstract Purpose of Review Bronchiectasis is a debilitating chronic lung disease
characterised by recurrent bacterial infection and colonisation with significant associated …